|
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
<b>Conclusion:</b> [<sup>11</sup>C]NMS-E973 is a PET tracer for <i>in vivo</i> visualisation of tumour HSP90 expression and can potentially be used for quantification of HSP90 occupancy.
|
30809293 |
2019 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
NMS-P715 in combination with fractionated doses of radiation significantly enhanced the tumor growth delay.
|
25722303 |
2015 |
|
Neoplasms
|
0.060 |
GeneticVariation
|
group |
BEFREE |
A series of compounds was synthesized leading to the identification of the potent and orally bioavailable JAK2 inhibitor 16 (NMS-P830), which showed an encouraging tumour growth inhibition in SET-2 xenograft tumour model, with evidence for JAK2 pathway suppression demonstrated by in vivo pharmacodynamic effects.
|
25882525 |
2015 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance.
|
25193492 |
2014 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Prior studies showed that MPS1 inhibition with the small molecule NMS-P715 limits tumor growth in xenograft models.
|
24282275 |
2014 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
In addition, NMS-P937 shows potential for combination in clinical settings with approved cytotoxic drugs, causing tumor regression in HT29 human colon adenocarcinoma xenografts upon combination with irinotecan and prolonged survival of animals in a disseminated model of acute myelogenous leukemia in combination with cytarabine.
|
22319201 |
2012 |
|
Parkinson Disease
|
0.050 |
Biomarker
|
disease |
BEFREE |
Neuromelanin sensitive magnetic resonance imaging (NMS-MRI) has been crucial in identifying abnormalities in the substantia nigra pars compacta (SNc) in Parkinson's disease (PD) as PD is characterized by loss of dopaminergic neurons in the SNc.
|
30870733 |
2019 |
|
Parkinson Disease
|
0.050 |
Biomarker
|
disease |
BEFREE |
We discuss the role of these neuroimaging techniques in elucidating the underlying pathophysiology of NMS in Parkinson's disease.
|
28802921 |
2017 |
|
Parkinson Disease
|
0.050 |
Biomarker
|
disease |
BEFREE |
The prevalence of each NMS among different PD motor subtypes was analyzed using x2 test.
|
29272011 |
2017 |
|
Parkinson Disease
|
0.050 |
Biomarker
|
disease |
BEFREE |
Our results suggested that stress induced NMS can accelerate neurodegenerative processes in the PD in a progressive or expedited manner.
|
28185878 |
2017 |
|
Parkinson Disease
|
0.050 |
Biomarker
|
disease |
BEFREE |
In late-stage PD, simple logistic regression analyses (controlling for age and gender) identified the following factors as associated with LS: number of NMS, general self-efficacy, walking difficulties and fatigue.
|
27726132 |
2017 |
|
Malignant Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
NMS-P515 ADME profile and its antitumor activity in a mouse xenograft cancer model render the compound eligible for further optimization.
|
30996792 |
2019 |
|
Primary malignant neoplasm
|
0.020 |
AlteredExpression
|
group |
BEFREE |
NMS-P515 ADME profile and its antitumor activity in a mouse xenograft cancer model render the compound eligible for further optimization.
|
30996792 |
2019 |
|
Glioblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
As a proapoptotic Bcl-2 member, PUMA was induced by NMS-E973 in a p53-dependent manner in glioblastoma in cell culture, thereby inducing apoptosis in glioblastoma cells.
|
29593424 |
2018 |
|
Glioblastoma Multiforme
|
0.020 |
Biomarker
|
disease |
BEFREE |
As a proapoptotic Bcl-2 member, PUMA was induced by NMS-E973 in a p53-dependent manner in glioblastoma in cell culture, thereby inducing apoptosis in glioblastoma cells.
|
29593424 |
2018 |
|
Glioblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Furthermore, NMS-P715 enhanced the radiosensitivity of GBM cells by decreased repair of DSBs and induction of postradiation mitotic catastrophe.
|
25722303 |
2015 |
|
Glioblastoma Multiforme
|
0.020 |
Biomarker
|
disease |
BEFREE |
Furthermore, NMS-P715 enhanced the radiosensitivity of GBM cells by decreased repair of DSBs and induction of postradiation mitotic catastrophe.
|
25722303 |
2015 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
NMS-P937 potently causes a mitotic cell-cycle arrest followed by apoptosis in cancer cell lines and inhibits xenograft tumor growth with clear PLK1-related mechanism of action at well-tolerated doses in mice after oral administration.
|
22319201 |
2012 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
NMS-P937 potently causes a mitotic cell-cycle arrest followed by apoptosis in cancer cell lines and inhibits xenograft tumor growth with clear PLK1-related mechanism of action at well-tolerated doses in mice after oral administration.
|
22319201 |
2012 |
|
Diarrhea
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
<b>Abbreviations</b>: 5-HT: 5-hydroxytryptamine/serotonin; BDNF: brain-derived neurotrophic factor; CRF: corticotrophin-releasing factor; EC: enterochromaffin; ENS: enteric nervous system; GI: gastrointestinal; GPCR: G-protein-coupled receptor; IBS (-D): irritable bowel syndrome (diarrhea predominant); LRP5/6: low-density lipoprotein receptor-related protein 5/6; MAPK: mitogen-activated protein kinase; NGF: nerve growth factor; NMS: neonatal-maternal separation; PI3K: phosphoinositode3-kinase; PLCγ: phospholipase c, gamma subtype; TrkA: tropomyosin receptor kinase A.
|
31272268 |
2019 |
|
Influenza
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
NMS-873 shows potent antiviral activity with low-nanomolar EC<sub>50</sub>s against multiple human influenza A and B viruses, including adamantine-, oseltamivir-, or double resistant strains.
|
30930289 |
2019 |
|
Irritable Bowel Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
<b>Abbreviations</b>: 5-HT: 5-hydroxytryptamine/serotonin; BDNF: brain-derived neurotrophic factor; CRF: corticotrophin-releasing factor; EC: enterochromaffin; ENS: enteric nervous system; GI: gastrointestinal; GPCR: G-protein-coupled receptor; IBS (-D): irritable bowel syndrome (diarrhea predominant); LRP5/6: low-density lipoprotein receptor-related protein 5/6; MAPK: mitogen-activated protein kinase; NGF: nerve growth factor; NMS: neonatal-maternal separation; PI3K: phosphoinositode3-kinase; PLCγ: phospholipase c, gamma subtype; TrkA: tropomyosin receptor kinase A.
|
31272268 |
2019 |
|
Caffeine related disorders
|
0.010 |
GeneticVariation
|
group |
BEFREE |
The purpose of this work was to quantify cocaine and cutting agents in 116 illicit samples from NMS Labs, Willow Grove, PA, U.S. Gas chromatography - mass spectrometry (GC-MS) and handle-portable gas chromatography toroidal ion trap mass spectrometry (GC-TMS) were used as screening methods A liquid chromatography tandem mass spectrometry (LC-MS/MS) method was developed and validated for the quantification of cocaine, levamisole, benzocaine, phenacetin, hydroxyzine, theophylline, diltiazem, acetaminophen and caffeine.
|
30634141 |
2019 |
|
Influenza A
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
NMS-873 shows potent antiviral activity with low-nanomolar EC<sub>50</sub>s against multiple human influenza A and B viruses, including adamantine-, oseltamivir-, or double resistant strains.
|
30930289 |
2019 |
|
Seizures
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Moreover, VU0486846 shows no interaction with antagonist binding at the orthosteric acetylcholine (ACh) site (e.g., neither bitopic nor displaying negative cooperativity with [<sup>3</sup>H]-NMS binding at the orthosteric site), no seizure liability at high brain exposures, and no cholinergic AEs.
|
29701957 |
2018 |